Cardiff Oncology, Inc. CRDF
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
2/9
Piotroski F — financial health
-20.45
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $593,000 | -$45.9M | — | -$38.0M | $45.4M |
| 2024 | $683,000 | -$45.4M | — | -$37.8M | $82.9M |
| 2023 | $488,000 | -$41.4M | — | -$31.5M | $69.7M |
| 2022 | $386,000 | -$38.7M | — | -$34.8M | $106.3M |
| 2021 | $359,000 | -$28.3M | — | -$23.2M | $140.4M |
| 2020 | $366,000 | -$19.3M | — | -$16.5M | $128.2M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Mohindru Mani | Chief Executive Officer | 2026-06-18 | Buy | 24,703 | $1.21 |
| PACE GARY W | director | 2026-06-18 | Buy | 30,000 | $1.22 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -20.45 (distress)
- Working capital / assets 0.707
- Retained earnings / assets -6.949
- EBIT / assets -0.791
- Equity / liabilities 2.751
Source: SEC EDGAR filings · CIK 0001213037 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.